A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma
This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one of the following additional controller medications: long-acting beta-agonists (LABA), leukotriene modifier (LTM), long-acting muscarinic antagonist (LAMA), or long-acting theophylline preparation. The total duration of this study for each participant is approximately 70 weeks including screening, run-in, treatment, and follow-up.
Inclusion Criteria:
Exclusion Criteria:
Warwick, Rhode Island 02865, United States
Mendoza, Mendoza City, M5500CCG, Argentina
Rosario, S2000JKE, Argentina
Sofia, 1431, Bulgaria
Ostrava-Poruba, 708 00, Czechia
Mainz, 55131, Germany
Krakow, 31-637, Poland
Lodz, 90-153, Poland
Cluj-Napoca, 400371, Romania
Craiova, 200515, Romania
Yaroslavl, Moscow Oblast 150003, Russia
Moscow, Sankt-Peterburg 117574, Russia
Kemerovo, 650099, Russia
Moscow, 115446, Russia
Chernivtsi, Chernihiv Governorate 58005, Ukraine
Zaporizhzhya, Kherson Governorate 69104, Ukraine
Kyiv, KIEV Governorate 02091, Ukraine
Dnipro, 49000, Ukraine
Dnipropetrovsk, 49027, Ukraine
Kharkiv, 61039, Ukraine
Kyiv, 03680, Ukraine